The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 5 SUPPL., 2009, Pages 61-70

  Allen, Matthew R ^a   Burr, David B ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE INFECTION; BONE REMODELING; COMORBIDITY; DIABETES MELLITUS; DRUG DOSE REDUCTION; HUMAN; INFECTION; JAW OSTEONECROSIS; MOUTH MUCOSA; OSTEOCYTE; SMOKING; TOOTH EXTRACTION;

ACTINOMYCOSIS, CERVICOFACIAL; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; HUMANS; JAW; JAW DISEASES; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOCYTES; OSTEONECROSIS;

EID: 64249118767     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.01.007     Document Type: Article

References (110)

1. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479
2. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
3. Mehrotra B., Fantasia J., Nissel-Horowitz S., et al. Osteonecrosis of the maxilla: An unusual complication of prolonged bisphosphonate therapy. A case report [abstract]. Proc Am Soc Clin Oncol 22 (2003) 795
4. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
5. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (2003) 1104
6. Amler M.H., Johnson P.L., and Salman I. Histological and histochemical investigation of human alveolar socket healing in undisturbed extraction wounds. J Am Dent Assoc 61 (1960) 32
7. Cardaropoli G., Araujo M., and Lindhe J. Dynamics of bone tissue formation in tooth extraction sites. An experimental study in dogs. J Clin Periodontol 30 (2003) 809
8. Reid I.R., Bolland M.J., and Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318
9. Reid I.R., and Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 38 (2009) 107
10. Mavrokokki T., Cheng A., Stein B., et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415
11. Rubegni P., and Fimiani M. Images in clinical medicine. Bisphosphonate-associated contact stomatitis. N Engl J Med 355 (2006) e25
12. Reddy G.T., Kumar T.M., and Veena K.M. Formulation and evaluation of alendronate sodium gel for the treatment of bone resorptive lesions in periodontitis. Drug Deliv 12 (2005) 217
13. Lin J.H. Bisphosphonates: A review of their pharmacokinetic properties. Bone 18 (1996) 75
14. Russell R.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19 (2008) 733
15. Russell R.G., Xia Z., Dunford J.E., et al. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117 (2007) 209
16. Rodan G.A., and Fleisch H.A. Bisphosphonates: Mechanisms of action. J Clin Invest 97 (1996) 2692
17. Allen M.R., Iwata K., Phipps R., et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39 (2006) 872
18. Mashiba T., Turner C.H., Hirano T., et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524
19. Allen M.R., and Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22 (2007) 1759
20. Allen M.R., and Burr D.B. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66 (2008) 987
21. Boivin G.Y., Chavassieux P.M., Santora A.C., et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 687
22. McDonald M.M., Dulai S., Godfrey C., et al. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 43 (2008) 653
23. Plotkin L.I., Aguirre J.I., Kousteni S., et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280 (2005) 7317
24. Idris A.I., Rojas J., Greig I.R., et al. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82 (2008) 191
25. Follet H., Li J., Phipps R.J., et al. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 40 (2007) 1172
26. Plotkin L.I., Weinstein R.S., Parfitt A.M., et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104 (1999) 1363
27. Boyce R.W., Paddock C.L., Gleason J.R., et al. The effects of risedronate on canine cancellous bone remodeling: Three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 10 (1995) 211
28. Eriksen E.F., Melsen F., Sod E., et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620
29. Iwata K., Li J., Follet H., et al. Bisphosphonates suppress periosteal osteoblast activity independent of resorption in rat femur and tibia. Bone 39 (2006) 1053
30. Allen M.R., Follet H., Khurana M., et al. Anti-remodeling agents influence osteoblast activity differently in modeling- and remodeling-associated bone formation. Calcif Tissue Int 79 (2006) 255
31. Allen M.R., Reinwald S., and Burr D.B. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 82 (2008) 354
32. Mashiba T., Hirano T., Turner C.H., et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15 (2000) 613
33. Reinwald S., and Burr D. Review of nonprimate, large animal models for osteoporosis research. J Bone Miner Res 23 (2008) 1353
34. Garetto L.P., Chen J., Parr J.A., et al. Remodeling dynamics of bone supporting rigidly fixed titanium implants: A histomorphometric comparison in four species including humans. Implant Dent 4 (1995) 235
35. Han Z.H., Palnitkar S., Rao D.S., et al. Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: Implications for mechanisms of bone loss. J Bone Miner Res 12 (1997) 498
36. Huja S.S., Fernandez S.A., Hill K.J., et al. Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol 288 (2006) 1243
37. Garetto L.P., and Tricker N.D. Remodeling of bone surrounding the implant interface. In: Garetto L.P., Turner C.H., Duncan R.L., et al. (Eds). Bridging the Gap Between Dental & Orthopaedic Implants. 3rd Annual Indiana Conference. Indianapolis, IN (1998)
38. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (2005) 8580
39. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2006) 968
40. Corso A., Varettoni M., Zappasodi P., et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21 (2007) 1545
41. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22 (2007) 1832
42. Lipton A., Steger G.G., Figueroa J., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25 (2007) 4431
43. Helfrich M.H. Osteoclast diseases and dental abnormalities. Arch Oral Biol 50 (2005) 115
44. Barry C.P., Ryan C.D., and Stassen L.F. Osteomyelitis of the maxilla secondary to osteopetrosis: A report of 2 cases in sisters. J Oral Maxillofac Surg 65 (2007) 144
45. Johnston Jr. C.C., Lavy N., Lord T., et al. Osteopetrosis. A clinical, genetic, metabolic, and morphologic study of the dominantly inherited, benign form. Medicine (Baltimore) 47 (1968) 149
46. Waguespack S.G., Koller D.L., White K.E., et al. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 18 (2003) 1513
47. Ruggiero S.L., and Drew S.J. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86 (2007) 1013
48. Bathi R.J., and Masur V.N. Pyknodysostosis-A report of two cases with a brief review of the literature. Int J Oral Maxillofac Surg 29 (2000) 439
49. Dimitrakopoulos I., Magopoulos C., and Katopodi T. Mandibular osteomyelitis in a patient with pyknodysostosis: A case report of a 50-year misdiagnosis. J Oral Maxillofac Surg 65 (2007) 580
50. Harper R.P., and Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 65 (2007) 573
51. Lau A.N., Ali S.H., and Adachi J.D. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH (1-34)] therapy. Osteoporos Int 19 Suppl 1 (2008) S80
52. Wang H.L., Weber D., and McCauley L.K. Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report. J Periodontol 78 (2007) 584
53. Malmgren B., Astrom E., and Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 37 (2008) 196
54. Schwartz S., Joseph C., Iera D., et al. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: A case series. J Can Dent Assoc 74 (2008) 537
55. Kingsmill V.J. Post-extraction remodeling of the adult mandible. Crit Rev Oral Biol Med 10 (1999) 384
56. Li C., Mori S., Li J., et al. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 16 (2001) 429
57. Li J., Mori S., Kaji Y., et al. Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res 15 (2000) 2042
58. Peter C.P., Cook W.O., Nunamaker D.M., et al. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14 (1996) 74
59. Altundal H., and Guvener O. The effect of alendronate on resorption of the alveolar bone following tooth extraction. Int J Oral Maxillofac Surg 33 (2004) 286
60. Olson H.M., and Hagen A. Inhibition of post-extraction alveolar ridge resorption in rats by dichloromethane diphosphonate. J Periodontal Res 17 (1982) 669
61. Bonewald L.F. Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci 1116 (2007) 281
62. Turner C.H., Robling A.G., Duncan R.L., et al. Do bone cells behave like a neuronal network?. Calcif Tissue Int 70 (2002) 435
63. Weinstein R.S., Jilka R.L., Parfitt A.M., et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102 (1998) 274
64. Enlow D.H. Functions of the Haversian system. Am J Anat 110 (1962) 269
65. Frost H.M. In vivo osteocyte death. J Bone Joint Surg Am 42 (1960) 138
66. Burr D.B., and Hooser M. Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone 17 (1995) 431
67. Frost H.M. Micropetrosis. J Bone Joint Surg Am 42 (1960) 144
68. Hansen T., Kunkel M., Weber A., et al. Osteonecrosis of the jaws in patients treated with bisphosphonates-Histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35 (2006) 155
69. Allen M.R. Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs 189 (2009) 289
70. Masarachia P., Weinreb M., Balena R., et al. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19 (1996) 281
71. Lin J.H., Duggan D.E., Chen I.W., et al. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19 (1991) 926
72. Roelofs A.J., Coxon F.P., Ebetino F.H., et al. Use of a fluorescent analogue of risedronate to study localization and cellular uptake of bisphosphonates in vivo. Bone 42 (2008) S85
73. Plotkin L.I., Manolagas S.C., and Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 277 (2002) 8648
74. Plotkin L.I., Manolagas S.C., and Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39 (2006) 443
75. Plotkin L.I., Lezcano V., Thostenson J., et al. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 23 (2008) 1712
76. Nancollas G.H., Tang R., Phipps R.J., et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38 (2006) 617
77. Leu C.T., Luegmayr E., Freedman L.P., et al. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38 (2006) 628
78. Kim H.K. Introduction to osteonecrosis of the femoral head (OFH) and osteonecrosis of the jaw (ONJ). J Musculoskelet Neuronal Interact 7 (2007) 350
79. Store G., and Boysen M. Mandibular osteoradionecrosis: Clinical behaviour and diagnostic aspects. Clin Otolaryngol Allied Sci 25 (2000) 378
80. Store G., and Grandstrom G. Osteoradionecrosis of the mandible: A microradiographic study of cortical bone. Scand J Plast Reconstr Hand Surg 33 (1999) 307
81. Guise T.A. Antitumor effects of bisphosphonates: Promising preclinical evidence. Cancer Treat Rev 34 Suppl 1 (2008) S19
82. Lipton A. Emerging role of bisphosphonates in the clinic-Antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34 Suppl 1 (2008) S25
83. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055
84. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538
85. Schenk R., Merz W.A., Muhlbauer R., et al. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11 (1973) 196
86. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682
87. Hansen T., Kunkel M., Springer E., et al. Actinomycosis of the jaws-Histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451 (2007) 1009
88. Estilo C.L., Fornier M., Farooki A., et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26 (2008) 4037
89. Parfitt A.M. The mechanism of coupling: A role for the vasculature. Bone 26 (2000) 319
90. Somerman M.J., and McCauley L.K. Bisphosphonates: Sacrificing the jaw to save the skeleton?. Bonekey Osteovision 3 (2006) 12
91. Adeyemo W.L., Ladeinde A.L., and Ogunlewe M.O. Clinical evaluation of post-extraction site wound healing. J Contemp Dent Pract 7 (2006) 40
92. Amler M.H. Disturbed healing of extraction wounds. J Oral Implantol 25 (1999) 179
93. Trombelli L., Farina R., Marzola A., et al. Modeling and remodeling of human extraction sockets. J Clin Periodontol 35 (2008) 630
94. Deckers M.M., Van Beek E.R., Van Der Pluijm G., et al. Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 17 (2002) 998
95. Tothill P., and MacPherson J.N. The distribution of blood flow to the whole skeleton in dogs, rabbits and rats measured with microspheres. Clin Phys Physiol Meas 7 (1986) 117
96. Rowell L.B. Human Cardiovascular Control (1993), Oxford University Press, New York, NY
97. Colleran P.N., Wilkerson M.K., Bloomfield S.A., et al. Alterations in skeletal perfusion with simulated microgravity: A possible mechanism for bone remodeling. J Appl Physiol 89 (2000) 1046
98. Bloomfield S.A., Hogan H.A., and Delp M.D. Decreases in bone blood flow and bone material properties in aging Fischer-344 rats. Clin Orthop Relat Res (2002) 248
99. Delp M.D., Colleran P.N., Wilkerson M.K., et al. Structural and functional remodeling of skeletal muscle microvasculature is induced by simulated microgravity. Am J Physiol Heart Circ Physiol 278 (2000) H1866
100. Lurie A.G., and Matteson S.R. 99MTc-diphosphonate bone imaging and uptake in healing rat extraction sockets. J Nucl Med 17 (1976) 688
101. McDougall I.R. Skeletal scintigraphy. West J Med 130 (1979) 503
102. Sedghizadeh P.P., Kumar S.K., Gorur A., et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 66 (2008) 767
103. Yeung M.K. Molecular and genetic analyses of Actinomyces spp. Crit Rev Oral Biol Med 10 (1999) 120
104. Nair S.P., Meghji S., Wilson M., et al. Bacterially induced bone destruction: Mechanisms and misconceptions. Infect Immun 64 (1996) 2371
105. Pap T., Claus A., Ohtsu S., et al. Osteoclast-independent bone resorption by fibroblast-like cells. Arthritis Res Ther 5 (2003) R163
106. Mundy G.R., and Elefteriou F. Boning up on ephrin signaling. Cell 126 (2006) 441
107. Zhao C., Irie N., Takada Y., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4 (2006) 111
108. Khamaisi M., Regev E., Yarom N., et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92 (2007) 1172
109. Wessel J.H., Dodson T.B., and Zavras A.I. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg 66 (2008) 625
110. AAOMS. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369